Clintrax looks to transform study start-up negotiations for CROs, sponsors

By Zachary Brennan contact

- Last updated on GMT

Clintrax looks to transform study start-up negotiations

Related tags: Medicine

With lawyers in more than 60 countries, North Carolina-based niche company Clintrax is looking to cut the time it takes to initiate a clinical trial by improving contract negotiations with investigator sites. 

In addition to its expertise, the company uses a cloud-based tracking system that allows sponsors and CROs read-only access to monitor the status of contract negotiations in real-time.

CEO Brandon Evans, former head of legal services at PRA Health Sciences, told that Clintrax saves companies an average of 40% on the time it takes to start a clinical trial -- typically 45 days for a CRO in the US.

CROs aren’t really interested in contract negotiations​,” Evans told us, adding that it’s mostly because they aren’t good at negotiating with sites and it’s not a money maker for them.

And when CROs and sponsors do negotiate with trial site investigators, especially in foreign countries, it’s usually local CRAs (clinical research associates) that do the negotiating, though they often don’t understand the legal nuances of the contract they’re working on, Evans said.

Ninety-seven percent of our staffers are lawyers​,” Evans added, noting that contract negotiations are easier in the US and Canada, and considerably more difficult and complex in France, Poland and Hungary, though the therapeutic area also plays a role.

Related news

Related products

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more